Key result
rHuEPO therapy is linked to ~27% higher plasma endothelin-1 levels at the end of hemodialysis.
Why the study?
The pathogenesis of recombinant human erythropoietin-induced hypertension in hemodialysis patients is uncertain, with emerging evidence of endothelial involvement.
Does rHuEPO therapy increase plasma endothelin-1 levels during hemodialysis in patients with end-stage renal disease?
Comparison
rHuEPO substitution vs no rHuEPO substitution
Design
Observational cohort study
Follow-up
During a single hemodialysis session
Authors
Loading...
rHuEPO-associated endothelin-1 elevation warrants no acute prescribing change; leaves open long-term vascular risk in hemodialysis.
Observational (n=19)
Does rHuEPO therapy increase plasma endothelin-1 levels during hemodialysis in patients with end-stage renal disease?
Absolute Event Rate: 1.62% vs 1.28%
p-value: p=<0.05
rHuEPO therapy in hemodialysis patients is associated with elevated plasma endothelin-1 levels, though this increase does not acutely cause arterial hypertension during the dialysis session.
Stefanidis et al. (2001) conducted an observational in End stage renal disease on hemodialysis (n=19). Recombinant human erythropoietin (rHuEPO) vs. No rHuEPO substitution was evaluated on Plasma endothelin-1 concentration at the end of hemodialysis (pg/ml) (p=<0.05). Recombinant human erythropoietin therapy in hemodialysis patients was associated with significantly higher plasma endothelin-1 levels at the end of dialysis (1.62 vs 1.28 pg/ml, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: